| 000 | 01852 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514011038.0 | ||
| 264 | 0 | _c20020123 | |
| 008 | 200201s 0 0 eng d | ||
| 022 | _a0167-6806 | ||
| 024 | 7 |
_a10.1023/a:1017980411398 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKonecny, G | |
| 245 | 0 | 0 |
_aDrug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. _h[electronic resource] |
| 260 |
_bBreast cancer research and treatment _cJun 2001 |
||
| 300 |
_a223-33 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacokinetics |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xpharmacokinetics |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacokinetics |
| 650 | 0 | 4 |
_aBreast Neoplasms _xpathology |
| 650 | 0 | 4 |
_aCarboplatin _xpharmacokinetics |
| 650 | 0 | 4 |
_aDeoxycytidine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
| 650 | 0 | 4 |
_aEpirubicin _xpharmacokinetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPaclitaxel _xpharmacokinetics |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 |
_aVinblastine _xanalogs & derivatives |
| 650 | 0 | 4 | _aVinorelbine |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aUntch, M | |
| 700 | 1 | _aSlamon, D | |
| 700 | 1 | _aBeryt, M | |
| 700 | 1 | _aKahlert, S | |
| 700 | 1 | _aFelber, M | |
| 700 | 1 | _aLanger, E | |
| 700 | 1 | _aLude, S | |
| 700 | 1 | _aHepp, H | |
| 700 | 1 | _aPegram, M | |
| 773 | 0 |
_tBreast cancer research and treatment _gvol. 67 _gno. 3 _gp. 223-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1023/a:1017980411398 _zAvailable from publisher's website |
| 999 |
_c11483863 _d11483863 |
||